SCHEMBL18292499

SCHEMBL18292499

O=C(Nc1nncs1)/C(=C\c1ccccc1)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.65
MAPT P10636 5/20 0.64
HTT P42858 3/20 0.64
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
KDM4E B2RXH2 2/20 0.64
POLB P06746 2/20 0.64
ALDH1A1 P00352 1/20 0.64
HPGD P15428 1/20 0.64
MAPK1 P28482 1/20 0.64
TAAR1 Q96RJ0 1/20 0.56
NPSR1 Q6W5P4 4/20 0.53
CYP2D6 P10635 3/20 0.53
CYP2C9 P11712 3/20 0.53
CYP2C19 P33261 3/20 0.53
CYP3A4 P08684 2/20 0.53
CRHBP P24387 1/20 0.53
CRHR2 Q13324 1/20 0.53
MIF P14174 1/20 0.52
CYP1A2 P05177 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2658596 0.88 LMNA (0.65) LMNAMAPTHTTMEN1KMT2A
SCHEMBL2658594 0.88 LMNA (0.65) LMNAMAPTHTTMEN1KMT2A
SCHEMBL2651722 0.85 GCK (0.72) LMNAMAPTHTTMEN1KMT2A
SCHEMBL2651727 0.85 GCK (0.72) LMNAMAPTHTTMEN1KMT2A
SCHEMBL11665349 0.79 MAPT (1.00) LMNAMAPTHTTMEN1KMT2A
SCHEMBL3379803 0.76 AQP4 (0.70) LMNAMEN1KMT2AKDM4EPOLB
SCHEMBL2660142 0.74 GCK (0.58) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL2660145 0.74 GCK (0.58) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL6380999 0.73 RAB9A (0.70) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL6380992 0.73 RAB9A (0.70) LMNAMAPTMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED (GB) 2016-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES CSNK1G1, CSNK1A1, CSNK1D LMNA 879/4885MAPT 20/4885HTT 1101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.